Jules I. Schwartz

Statistics

Publications

Citations

2.6K

H-Index

Active since

1964

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

United States Military Academy

University of Toledo

Pharmaceutical Product Development (United States)

Mercy St. Vincent Medical Center

Jules I. Schwartz is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, clinical pharmacology, and pharmacokinetics.

Publications per year

1964–2011

Publications

Inhibition of Exercise-Induced Bronchoconstriction by MK-571, a Potent Leukotriene D<sub>4</sub>–Receptor Antagonist

Patrick Manning, Richard M. Watson, Dorothy J. Margolskee et al. · New England Journal of Medicine · 1990 · 401 citations · Full text

Life Sciences, Pharmacology, Exercise Physiology +8

Comparative Inhibitory Activity of Rofecoxib, Meloxicam, Diclofenac, Ibuprofen, and Naproxen on COX‐2 versus COX‐1 in Healthy Volunteers

Anne Van Hecken, Jules I. Schwartz, Marleen Depré et al. · The Journal of Clinical Pharmacology · 2000 · 355 citations

Medicine, Pharmacology, Pharmacotherapy +13

Effect of Cyclooxygenase-2 Inhibition on Renal Function in Elderly Persons Receiving a Low-Salt Diet

Suzanne K. Swan, David W. Rudy, Kenneth C. Lasseter et al. · Annals of Internal Medicine · 2000 · 337 citations

Medicine, Pharmacology, Pharmacotherapy +12

Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal‐salt diet

Jules I. Schwartz, K. Vandormael, Marie-Pierre Malice et al. · Clinical Pharmacology & Therapeutics · 2002 · 158 citations

Pharmacy, Geriatric Medicine, Pharmacotherapy +11

In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics

Cuyue Tang, Magang Shou, Thomas H. Rushmore et al. · Pharmacogenetics · 2001 · 121 citations

Medicine, Pharmacokinetics, Pharmacology +16

1–5 of 44